Latest Safety News

Neurizon Therapeutics has formally responded to the FDA's clinical hold on its lead ALS drug NUZ-001, submitting new animal safety data. The company aims to join the HEALEY ALS Platform Trial by late 2025, pending regulatory approval.

Dimerix has secured a significant licensing agreement with Amicus Therapeutics for its kidney disease drug candidate DMX-200 in the US, receiving a US$30 million upfront payment and advancing its Phase 3 trial with FDA endorsement of a key clinical endpoint.

Newmont Corporation reported a robust second quarter in 2025, driven by higher gold prices, successful divestitures of non-core assets, and strong operational performance, reinforcing its financial strength and strategic focus.

Vection Technologies has secured $1 million in new AI contracts, including a significant third deal with Area 12 Consulting, boosting their partnership to $3.6 million in just ten weeks.

Karoon Energy reported a 25% jump in net revenue interest production for Q2 2025, driven by operational recovery and the Baúna FPSO acquisition. The company also advanced its Neon development with a significant resource upgrade.

SRJ Technologies has taken a strategic leap by acquiring a UAE entity registered with a regional National Oil Company, positioning itself for direct contracting in the Middle East energy sector. This move is supported by a recent capital raise and ongoing restructuring to sharpen its regional focus.

MAC Copper Limited delivered a standout June quarter with record daily copper output and sharply reduced costs, while advancing its strategic acquisition by Harmony Gold.

Podium Minerals has significantly expanded its Parks Reef project with a new Copper-Gold Zone resource, increasing the basket price by 18% and completing a $2.6 million oversubscribed capital raise.

Mount Gibson Iron Limited reports steady FY25 iron ore sales amid operational challenges and announces a strategic entry into gold with a 50% stake in the Central Tanami Project.

Lynas Rare Earths has achieved record quarterly production of key rare earth elements and reported a strong 38% increase in sales revenue, while advancing its Mt Weld expansion and signing strategic MOUs in Malaysia.

Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.

Talius Group has reported a net profit of $0.37 million for Q2 2025, driven by a 6% increase in subscriptions and strategic partnerships that expand its market reach in aged care technology.